Public health guidance: Seasonal influenza vaccination of children and pregnant women
The aim of this guidance document is to provide EU/EEA Member States and EU bodies with relevant information to make an informed decision on routine vaccination of healthy children and pregnant women with seasonal influenza vaccine. The options presented in this document are based on a systematic review of the literature and the opinions of a group of independent experts.
Seasonal influenza vaccination in Europe – Vaccination recommendations and coverage rates for 2012–13
This report provides an update on seasonal influenza immunisation policies and vaccination coverage rates in EU/EEA Member States for the 2012–13 influenza season.
Expert opinion on priority risk groups for influenza vaccination
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.
Seasonal influenza vaccination in Europe – Vaccination recommendations and coverage rates for 2013-14 and 2014-15
Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons.
Efficacy and safety of single and double doses of Ivermectin versus 7-day high dose Albendazole for chronic StrongyloidiasisArchived
A prospective, randomized, open study was conducted in which a 7-day course of oral albendazole 800 mg daily was compared with a single dose (200 microgram/kilogram body weight) or double doses, given 2 weeks apart, of ivermectin in Thai patients with chronic strongyloidiasis.
Systematic review and meta-analysis concerning the efficacy and effectiveness of seasonal influenza vaccines – (part 1)Archived
This is an authoritative independent evidence-based review and meta-analysis of the efficacy and effectiveness of influenza vaccines. It confines itself to trials and observational studies where diagnostic tests confirmed influenza infection as the end point.
Lower than usual: early influenza vaccine effectiveness in parts of Europe in season 2011/12Archived
A rapid communication published on April 12th 2012 describes the early results of the annual multicentre case-control study undertaken by the ECDC sponsored I-MOVE consortium whose work is coordinated by an Epiconcept team
Annual influenza vaccine effectiveness meeting 2013 – summary of discussions on obtained results and recommended future research focus
Influenza vaccine experts from thirteen EU countries and invited guests from Canada and the US gathered for three days July 1-3, 2013 in Annecy, France to report and discuss obtained national and pooled multi-country seasonal influenza vaccine effectiveness (VE) obtained in the 2012/2013 season. The meeting was co-organized by ECDC and Epiconcept.
Initial studies on seasonal influenza vaccine effectiveness for 2013/2014
The authors used a test-negative case control design to estimate the 2013/14 influenza vaccine effectiveness (VE) in patients seen with influenza-like illness as outpatients in Spain during December 2013-January 2014.
Effect of introducing high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children
This is the main finding of a recent article based on data from The Streptococcus pneumoniae Invasive Disease network (SpIDnet).